Jimandin (Sitagliptin)

Sitagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood glucose levels.

The appropriate dose of Jimandin is determined by a qualified prescriber based on the individual’s clinical condition, renal function and response to therapy. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for sitagliptin in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To request Jimandin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas or insulin, sitagliptin has a low risk of causing hypoglycaemia because its glucose‑dependent mechanism requires elevated blood sugar to act. Unlike metformin, it does not affect gastrointestinal absorption, but it does not replace the need for lifestyle modification.

Jimandin should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture. Keep the product out of reach of children and avoid exposure to direct sunlight or extreme heat.

Jimandin is taken orally, usually once daily, with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed.

The most serious adverse events linked to sitagliptin include pancreatitis, severe allergic reactions such as anaphylaxis, and joint pain that may indicate an underlying inflammatory condition. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or severe joint discomfort.

Jimandin is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is advised in individuals with a history of pancreatitis, severe renal impairment, or those taking other DPP‑4 inhibitors.